Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900842 | 1.00 | CYP2D6 (1.00) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| SCHEMBL30416731 | 1.00 | CYP2D6 (1.00) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| SCHEMBL19900950 | 1.00 | CYP2D6 (1.00) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| SCHEMBL19350963 | 1.00 | CYP2D6 (1.00) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL10802067 | 0.99 | CYP2D6 (0.98) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL30416719 | 0.99 | CYP2D6 (0.98) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL30387812 | 0.99 | CYP2D6 (0.98) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| SCHEMBL8704285 | 0.93 | CYP2D6 (0.88) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| Phosphoric Acid SCHEMBL20552775 | 0.93 | CYP2D6 (0.86) | CYP2D6HTR2AABCB1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL8707201 | 0.92 | CYP2D6 (0.86) | CYP2D6HTR2AABCB1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3503879-B1 | COMPOSITION COMPRISING (A) A DUAL AGENT ACTING AS A 5-HT2A RECEPTOR ANTAGONIST AND CYP2D6 INHIBITOR AND (B) AN NMDA RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF DISEASES INVOLVING GLUCOSE | Exciva GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | CYP2D6 9/4885HTR2A 1/4885ABCB1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.